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ABSTRACT 
Prostaglandin Dz (PGDz) is the most common prostaglandin type of tile 
rat brain. Recently a neurornodulator role for PGDz has been suggested. 
In the present work the central cardiovascular and thermal effects of 
PGDz were studied in urethane-anaesthetised rats. Mlen adrndnistered at 
the doses of 0.001-10 ~g/rat into the lateral cerebral ventricle(i.c.v.), 
PGD2 slightly increased the blood pressure, heart rate and body ternpera-
~ure. The highest dose caused also an initial hypotensive effect. Upon 
lntravenous injections PGD2 (0.1-10 ~g/rat) initially decreased and then 
weakly increased the blood pressure but had only negligible effects on 
heart rate and body temperature. Central pretreatment with sodium meclo-
fenamate or indomethacin (1 mg/rat i.c.v.) antagonised effectively all 
the recorded central effects of PGD2. 
The central cardiovascular and thermal effects of PGD2 were much 
weaker than those obtained earlier with other prostaglandins, such as 
PGF2a. and PGE2.. Therefore, in spite of its ablUldance in the brain PGD2 
may not be very important for the central cardiovascular and thermal reg-
ulation in the rat. 
INTRODUCTION 
Prostaglandin D£ (PG~) is the IOOst common prostaglandin type in the 
brain of the rat (2), but its possible physiological functions in the 
central nervous system are not known. Some investigators have suggested 
that prostaglandins may be involved in the central control of the cardio-
vascular and thermoregulatory systems (3,4,5). The highest activity of 
the PGD synthetase in the rat brain has been fOtmd in the hypothalanrus 
and thalamus (6), the brain areas important for cardiovascular (7) and 
thermal (3,8) homeostasis. Prostaglandins of the E-type are known to be 
highly active hyperthermic agents in the brain (8,9). In additi?n, cen-
tral administration of PGE2 or PGF~ induce strong dose-related Increas-
es in blood pressure, heart rate and body temperature of the urethane-
anaesthetised rat (1,4). Recently it has been reported that PGDz at a 
dose of 10 ~g/rat raise the blood pressure and heart rate, when adJ:dnis-
tered intracerebroventricularly (i.c.v.) to the urethane-anaesthetlsed 
rat (10). However, only two doses were used and therefore the dose-re-
sponse relationships are not known. 
1 A preliminary report of this work has been presented at the X~XII ~leet­
ing of the Scandinavian Pharmacological Society (1). 
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In the present study increasing doses of PGD2 were ~drrdniste~ed 
Lc.v. or intravenously (Lv.) to the urethane-anaesthetIsed rat In or-
der to obtain complete simultaneous cumulative dose-response curves for 
blood pressure, heart rate and body temperature. Since sodi~ mec1o-
fenamate interferes with the effects of exogenous prostaglandlns both 
in the peripheral tissues (11,12) and in the brain (4,13), it seemed 
worthwhile to investigate the influence of this agent on the central ef-
fects of PGDz. For comparison, the effect of indomethacin, an equally 
effective inhibitor of prostaglandin synthesis as sodium meclofenamate 
(14), was also studied. 
MATERIALS AND METHODS 
Male Wistar rats (260-360 g) were used. The rats were accoJ1Ddated 
to standard ambient conditions for at least one week before the experi-
ments. The lights were on from 6 a.m. to 6 p.m. and the room was com-
pletely dark during the remaining 12 hours. The temperature was kept at 
22 C and the relative humidity at 40%. lhe rats received standard rat 
pellets (Hankkija Oy., Helsinki) and tap water ad libitum. 
The rats were anaesthetised with urethane (1.5 g/kg intraperitoneal-
ly). The trachea was cannulated with a polyethylene tube and the rats 
were allowed to breathe spontaneously. The mean arterial blood pressure 
was measured from tile left feJ1Dral artery by means of a pressure trans-
ducer (llewlett Packard 1280). The heart rate was calculated from the 
pulse waves by reans of a rate computer (Hewlett Packard 8812 A). The 
left femoral vein was cannulated for intravenous injections. The rats 
were mounted in a stereotaxic instrument and tilted caudally so that the 
body fonned an angle of 10 degrees with the horizontal plane. Intrace-
rebroventricular injections were perforred as described by Paakkari(ls). 
Briefly, an injection needle was introduced into the right lateral ven-
tricle of the brain. A polyethylene catheter, filled with the drug or 
control solution to be infused, was attached to the needle and the de-
sired arount of the solution was allowed to flow slowly by virtue of the 
hydrostatic pressure. The proper position of the needle tip was ascer-
tained at the end of each experiment by an injection of dye (Giemsa So-
lution, Merck) into the cerebral ventricle. The body temperature was 
measured rectally with a temperature recorder (ELLAE instruments, type 
TE 3, Copenhagen), a probe being introduced 5 cm into the rectum. A 60 W 
heating lamp was placed 20 cm above the rat. This distance of the heat-
ing lamp was adequate to keep the body temperature of the control rats 
at 36.9 ± 0.3 C (mean ± s.e.m.) in an ambient temperature of 22 C. 
Administration of drugs 
Prostaglandin D2 (PGD2), kindly supplied by Dr. J. Pike of the 
Upjohn Companies, was dissolved in absolute ethanol and stored at -20 C. 
F~rther dilutions were made freshly each day in a modified Krebs-Ringer 
bIcarbonate buffer (4) for Lc.v. injections and in 0.9 %(w/v) NaCl 
(saline) for i.v. injections. The i.c.v. injections were performed in a 
volume of 10 jJl each and the Lv. injections in a volume of 0.15 ml each. 
~le control animals re~eived the same volume of the appropriate vehicle 
In each case. IncreasIng doses of PGD2 were administered Lc.v. at 20 
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min intervals in order to obtain cumulative dose-response curves. TI1is 
interval was chosen because in the preliminary experiments (6 rats for 
each dose) the maximtnn tachycardic and hyperthermic effects of PGD 2 were 
reached 10-20 min after each Lc.v. injection. The maximum pressor ef-
fect, however, became apparent 5 min after each Lc.v. injection. For 
comparison, the i.v. injections were also repeated at 20 nUn intervals 
to make sure that the effects induced by centrally administered PGD 2 
were not due to a leakage of the drug into the peripheral circulation. 
Indomethacin (Or ion Pharmaceutical Co., Helsinki) was dissolved in 
0.25 N NaOH and sodium meclofenamate monohydrate (Parke, Davis & Co.) in 
saline. The effect of central pretreatment Witil indomethacin or sodium 
meclofenamate on the central actions of PGDz was investigated by inject-
ing these drugs i.c.v. 20 min before commencement of the adrrUnistration 
of increasing doses of PGDzi.c.v. The control animals received the same 
volume of saline Lc.v. (both of the drug solutions were at the pH of 
6.8-7.3). 
The Student's t-test was used to calculate the statistical signif-
icance of the differences between the control and experimental groups. 
RESULTS 
Effects of prostaglandin DZ in non-pretreated rats 
Intracerebroventricularly, PGDz at the doses of 0.001-1 ~g/rat in-
duced rises of blood pressure. The maxirm.nn pressor effect was reached 
5 rnin after each i.c.v. injection. The highest dose of 10 ~g/rat caQsed 
an initial hypotensive effect with its maximum at 1-2 min after each in-
jection. Intravenous administration of PGD2 (0.1-10 ]..lg/rat induced in-
itial falls in blood pressure followed by slight increases in blood pres-
sure. The maxinrum hypo tens i ve effect was reached 1-2 min after each i. v. 
injection. (Fig. 1) 
PGDz induced a dose-related tachycardic effect, when adrrUnistercd at 
the doses of 0.001-10 ]..lg/rat Lc.v. The maximum effect \;Jas reached 10-
20 min after each Lc.v. injection. Intravenously, the same doses slight-
ly increased the heart rate. (Fig. 2) 
PGDz i.c.v. (0.001-10 ~g/rat) increased dose-dependently also the 
body temperature. The maximum hyperthennic effect was reached 20 min 
after each i.c.v. injection. Intravenously, the same doses caused only 
negligible increases in body temperature. (Fig. 3). 
Effects of indomethacin and sodium meclofenamate 
Centrally adndnistered indomethacin or sodium meclofenamate (1 mg/ 
rat i.c.v.) had no significant effects of their own on the blood pressure, 
heart rate or body temperature of urethane-anaesthetised rats. There were 
thus no statistically significant differences in the baseline levels of 
blood pressure, heart rate and body temperature between indomethacin, 
sodium meclofenamate and vehicle pretreated groups before commencement 
of the administrations of PGD2i.c.v. (see Fig. 4). 
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Figure 1. Time-close-response effect of PGD2 on blood pressure in ure-
thane-anaesthetised rats. Increasing doses of PGD~ were administered 
i.c.v. Ce-e) or Lv. C-___ at 20 min intervals. Open circles repre-
sen t the vehicle i. c. v. controls. The initial blood pressure level (lOOan 
: s.e.m.) before commencement of the vehicle or PGD2 administrations was 
110 : 10 mm Hg in the control group, 103 ± 7 mm Hg in the PGD2 i.c.v. ~~up and 109 = 4 mm Hg in the PGDz i.v. group. The differences between 
the initial levels of the groups are not statistically significant. The 
PGD2-induced hypertensive effect at the i.c.v. doses of 0.001-10 ~g/rat 
is Si~lificant at the p<U.OS-O.OOl level as compared to the control val-
ues .. TI1~ ~hanges in blood pressure induced by PGD2 i.v. CO.l-lO ~g/rat) 
are SIgnIfIcant at the p<O.TIS-0.005 level as compared to the control 
$TOUP· The.differences in the changes in blood pressure between the 
I.C.V. and 1.V. groups at the doses of 0.1-10 ~g/rat are significant at 
th~ p<O.OS-O.OOS level. Vertical bars indicate s.e.m. Each group com-
prIsed 6 ra ts . 
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figure 2. Time-dose-response effect of PGD,;: on heart rate in urethane-
anaesthetised rats. Increasing doses of PGDz were adrrUnistered i.c.v. 
(e-e) or i. v. (.-.) at 20 min intervals. Open circles represent the 
vehicle i.c.v. controls. TIle initial heart rate level (mean ± s.e.m.) be-
fore cOlTlJOOncement of the vehicle or PGDz acbninistrations was 445 ! 10 
beats/min in the control group, 445 ± 15 beats/min in the PGD~ i.c.v. 
group and 445 l' 5 beats/min in the PGD Lv. group. The tachycardic ef-
fect of PGDz Lc.v. (0.OUl-10 ~g/rat) is significant at the p<O.OS-O.OOl 
level as compared to tile control values. TIle changes in heart rate in-
duced by PGDz i.v. at the doses of 0.001-10 ~g/rat are significant at 
the p<O.05-0.005 level as compared to the control values. The differ-
ences in the PGDz-induced changes between the i.c.v. and Lv. groups are 
significant at the p<O.05-0.00S level (0.001-10 ilg/rat). Vertical bars 
indicate s.e.m. Each group comprised 6 rats. 
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Fi gure 3. Time-dose-response effect of PGD2 on body temperature in 
urethane-anaesthetised rats. Increasing doses of PGDz were adminis-
tered i. c. v. (e -e) or i. v . (.-.) at 20 min intervals. Open circles 
represent the vehicle i.c.v. controls. The initial body temperature 
level (mean ± s.e.m.) before cOlIllrenceJOOnt of the administrations of 
vehicle or PGD2 was 36.3 ! 0.2 C in the control group, 3S.7 - 0.2 C in 
the PGD2 i. c. v. group and 3S. 8 ! 0.2 C in the PGD2 Lv. group. The 
differences between the initial levels of the groups is significant at 
the p<O.OS level. The rises of body temperature induced by PGD2 i.c.v. 
(O.OOl-O.Ul~g/rat)are significant at the p<O.OS-O.OOS level and at the 
doses of 0.1-10 ~g/rat at the p<O.OOl level as compared to the control 
values. The changes induced by PGD2 Lv. are significant at the doses 
of 0.001-10 ~g/rat at the p<O.OS-O.OOl level as compared to the control 
group. Differences in the changes in body temperature between the Lc. v. 
and Lv. groups are significant at the doses of 0.1-10 ~g/rat at the 
p<O.OS-O.OOS level. Vertical bars indicate s.e.m. Each group comprised 
6 rats. 
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Figure 4. Effect of Lc.v. administered PGDz on blood pressure (B.P.), 
heart rate (H.R.) and body temperature (B. T.) in indoJOOthacin and sodium 
Ireclofenamate pretreated rats. IndoJOOthacin, I mg/rat (A-A), sodium 
IOOclofenamate, 1 mg/rat c._e), or vehicle (0 -:")) was administered 
i.c.v. 20 ndn before commencement of the adrrUnistrations of PGD2 • In-
creasing doses of PGD2 were administered i.c.v. at 20 min intervals. The 
initial levels for B.P., H.R. and B.T. (me~ ± s.e.m.) b~fore commence-
ment of t~e PGD2 administrations were 103 - 7 mm Hg, 440 - 15 beats/~n 
and 35.8 - 0.2 C in the control group, 100 i 5 mm Hg, 440 ± 10 beats/man 
and 3S. 8 !: 0.3 C in the indoJOO thacin pre trea ted group, and 90 l' 7 nun Hg, 
430 ± 10 beats/min and 35.4 ± 0.3 C in the sodium meclofenamate pretreat-
ed group. The differences between the initial levels of the groups are 
not statistically significant. Vertical bars indicate s.e.m. Each 
group comprised 6 rats .• p<O.OS, •• p<0.005 and ••• p<O.OO.l V6. 
con trol group. -
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Effects of prostaglandin DZ in indometha~in and 
sodium meclofenamate pretreated rats (FIg. 4) 
Central pretreatment with indomethacin (1 mg/rat i.c.v.~ effecti-
vely antagonised the hypertensive, tachycardic and hyperthermlc effects 
of centrally administered PGDz • 
Pre~reatment of the rats with sodium meclofenamate (1 mg/rat i.c.v.) 
completely blunted the PGDz-induced central rises of blood pressure, 
heart rate and body temperature. 
DISCUSSION 
PGDz i.c.v. at the doses of 0.001-10 ~g/rat raised the blood.p:es-
sure of uretilane-anaesthetised rats. The highest dose induced an llll-
tial decrease in blood pressure, followed by the hypertensive response. 
I.c.v. administered PGD2 also dose-dependently increased the heart rate 
and body temperature of the rats. The effects of PGD2 were not due t<;> 
any leakage of the drug into the peripheral circulation but to an actIon 
upon the central nervous system, since upon intravenous injections the 
same doses first decreased and then only slightly increased the blood 
pressure and had only weak tachycardic and hyperthermic effects. The 
antagonism of the central cardiovascular and thermal effects of PGD2 by 
i. c. v. pretrea tments with indomethacin or sodium meclofenamate further 
supports the assumption of a central site of action for PGD2' 
In agreement with the present results i.c.v. administered PGDz at 
a dose of 10 ~g/rat slightly increased the blood pressure and heart rate 
of the ureU1ane-anaesthetised rat (10). Negligible rise of body tempe-
rature has also been reported following i.c.v. injections of PGDz in 
conscious rats (16) and cats (17). The rise of blood pressure after the 
administration of the smallest dose of PGD2 preceded the increases in 
heart rate and body temperature. Hence, the hypertensive response to 
PGDz is not a consequence of the increased body temperature, and PGDz 
see~ to be more potent in inducing changes in blood pressure than in 
heart rate and body temperature. 
PGDz is the lIJ)st COJI1lOOn prostaglandin type in the rat brain (2). 
Therefore the fonnation of PGD2 in the brain might, under S0100 physiolo-
gical or pathophysiological conditions, influence cardiovascular and 
the:rm:>regulatory systems. In fact, the central effects of PGD2 were very 
similar to those of arachidonic acid (18,19), the precursor of prosta-
glandins (14). However, PGDz was less potent than PGE z (1) or PGFza (4, 
10) ~ inducing increases in blood pressure, heart rate and body tempera-
ture In the urethane-anaesthetised rat. Therefore, in spite of the abun-
dance of PGDz in the rat brain, the weak potency does not suggest an im-
portant role for this compound in the central control of the cardiovas-
cular and thenooregulatory systems. 
Central pretreatment with indomethacin or sodium meclofenamate ef-
fec~i~ely antagonised the cardiovascular and thermal responses to i.c.v. 
adminIstered PGDz• In agreement with the present findings an antagonism 
of the effects of exogenous prostaglandins by fenarnates and indomethacin 
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has been reported in several tissues: Sodium meclofenamate and other 
fe~amate7 antagonise th: effects of exogenous prostaglandins in rat, 
gumea-plg and human allJl'entary muscle (11,12), human bronchial nruscle 
(20)! an~ these drugs attenuate the PGF 2a-induced bradycardia and hypo-
~enslon ln the cat· (21) and prostaglandin-induced gastric acid secretion 
ill the rat (22). Furthenoore, the central hypotensive effect of PGI 2 
was antagonised by sodium meclofenamate (13). Indomethacin has been 
repqrted to blunt the PGDz-induced contractions of the longitudinal nrus-
cle of rat gastric fundus (12) and to reduce submaximal contractions to 
PGE 1 in gerbil colon (23). Antagonism of the prostaglandin action by 
indumethacin has also been demonstrated in rat uterus (24) and in iso-
lated guinea-pig ileum and rabbit ear preparations (25). Indomethacin 
partly antagonised also the central effects of PGE z on blood pressure, 
heart rate and body temperature of the urethane-anaesthetised rat, while 
sodium meclofenamate blunted only the hypertensive effect of centrally 
administered PGE z (1). Indomethacin and mefenamdc acid both interfere 
with tile 3H-PGE 1-binding in rat epididymal fat cells suggesting that 
tllese agents may directly interact with PGE 1 at a common receptor (23). 
However, both indomethacin and fenamates effectively inhibit also the 
synthesis of prostaglandins (14). The total amount of prostaglandins, 
endogenous plus exogenous, present at the receptors may be decreased by 
inhibitors of prostaglandin synthesis. Therefore the possibility cannot 
be excluded that the effects of indOIrethacin and sodium lOOclofenamate 
might be at least parly due to the inhibition of the endogenous prosta-
glandin synthesis and not solely to the blockade of prostaglandin re-
ceptors. 
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